Patents-Review.com
🔗 Permalink
Assignee profile:

Byondis B.V.

City:

Nijmegen

Country:

Netherlands

Published Applications:

19

Last publication date:

2023-10-26

Patent Grants:

19

Last grant date:

2025-07-08

Top Inventors for applications by Byondis B.V.

These are the the leading inventors for applications assigned to Byondis B.V.:

Recent patent applications by Byondis B.V.

Byondis B.V. based in Nijmegen, NL has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2023-10-26 ✅ Patent 12,350,345 granted on 2025-07-08
US20230338570A1
Human necessities

DUAL CONJUGATION PROCESS FOR PREPARING ANTIBODY-DRUG CONJUGATES

 #2 | 2022-06-23 ✅ Patent 11,718,681 granted on 2023-08-08
US20220195063A1
Chemistry; metallurgy

Anti-SIRP α antibodies

 #3 | 2021-12-16 ✅ Patent 12,180,552 granted on 2024-12-31
US20210388115A1
Chemistry; metallurgy

Site-specific conjugation of linker drugs to antibodies and resulting ADCs

 #4 | 2021-12-16 ✅ Patent 12,180,295 granted on 2024-12-31
US20210388107A1
Chemistry; metallurgy

Humanized anti-SIRPα antibodies

 #5 | 2021-12-16 ✅ Patent 12,178,881 granted on 2024-12-31
US20210386867A1
Human necessities

Filterable duocarmycin-containing antibody-drug conjugate compositions and related methods

 #6 | 2021-10-14 ✅ Patent 11,584,801 granted on 2023-02-21
US20210317231A1
Chemistry; metallurgy

Anti-5T4 antibodies and antibody-drug conjugates

 #7 | 2021-03-11 ✅ Patent 11,274,159 granted on 2022-03-15
US20210070874A1
Chemistry; metallurgy

Anti-SIRPα antibodies

 #8 | 2020-11-26 ✅ Patent 11,633,492 granted on 2023-04-25
US20200368362A1
Human necessities

Process for the synthesis of linker-drug vc-seco-DUBA

 #9 | 2020-09-24 ✅ Patent 11,419,944 granted on 2022-08-23
US20200297859A1
Human necessities

Non-linear self-immolative linkers and conjugates thereof

 #10 | 2020-09-03 ✅ Patent 11,696,958 granted on 2023-07-11
US20200276331A1
Human necessities

Dual conjugation process for preparing antibody-drug conjugates

 #11 | 2020-01-09 ✅ Patent 10,815,194 granted on 2020-10-27
US20200010408A1
Chemistry; metallurgy

Process for the preparation of mono-protected α,ω-diamino alkanes

 #12 | 2019-12-26 ✅ Patent 10,814,009 granted on 2020-10-27
US20190388552A1
Human necessities

Selective reduction of cysteine-engineered antibodies

 #13 | 2019-12-05 ✅ Patent 11,104,968 granted on 2021-08-31
US20190368000A1
Chemistry; metallurgy

Site-specific conjugation of linker drugs to antibodies and resulting ADCS

 #14 | 2019-12-05 ✅ Patent 11,136,633 granted on 2021-10-05
US20190367999A1
Chemistry; metallurgy

Site-specific conjugation of linker drugs to antibodies and resulting ADCS

 #15 | 2019-10-17 ✅ Patent 11,382,982 granted on 2022-07-12
US20190314513A1
Human necessities

Duocarmycin ADCs showing improved in vivo antitumor activity

 #16 | 2019-07-18 ✅ Patent 11,077,204 granted on 2021-08-03
US20190216942A9
Human necessities

Compositions comprising antibody-duocarmycin drug conjugates

 #17 | 2019-06-27 ✅ Patent 11,008,400 granted on 2021-05-18
US20190194346A1
Chemistry; metallurgy

Anti-5T4 antibodies and antibody-drug conjugates

 #18 | 2018-10-04 ✅ Patent 10,821,191 granted on 2020-11-03
US20180280533A1
Human necessities

SYD985 treatment of T-DM1 refractory cancer patients

 #19 | 2018-07-19 ✅ Patent 11,077,204 granted on 2021-08-03
US20180200382A1
Human necessities

Compositions comprising antibody-duocarmycin drug conjugates

Also check out Byondis B.V.'s (Nijmegen, Netherlands) applicant profile with 22 patent applications submitted.

AssigneeID:

358183 ⎘